产品
编 号：F609255
分子式：C7H9NO5S2
分子量：251.28
分子式：C7H9NO5S2
分子量：251.28
产品类型
规格
价格
是否有货
结构图
CAS No: 950834-06-7
产品详情
生物活性：
CXL-1020 is a hydroxylamine-based nitroxyl (HNO) donor. CXL-1020 improves cardiac inotropy/lusitropy and Ca2+ cycling in rats with abnormal relaxation. CXL-1020 induces vasorelaxation and improves cardiac function in canine models. CXL-1020 has been used to research systolic heart failure and stable heart failure.
体内研究：
CXL-1020 (100 μg/kg/min; infusion for 30 min) improves hemodynamics and cardiac function, and enhances both diastolic and systolic performance in mice.CXL-1020 (3 and 10 mg/kg/min; 4-hour intravenous infusion) improves left ventricular systolic and diastolic function in dogs with advanced heart failure.Animal Model:Adult male Sprague-Dawley rats (250-350 g; induced cardiac dysfunction byisoproterenol)
Dosage:100 μg/kg/min
Administration:For 30 min
Result:Improved hemodynamics and cardiac function in normal rats, and enhanced both diastolic and systolic performance in cardiac dysfunction mice.
Animal Model:Dogs (coronary microembolization-induced heart failure)3 and 10 mg/kg/min
Dosage:3 and 10 mg/kg/min
Administration:4-hour intravenous infusion
Result:Decreased systolic aortic pressure (AoP) modestly; significantly increased EF and deceleration time of early mitral inflow velocity (DT) and significantly lowered left ventricular (LV) end-systolic volume (ESV), LV end-diastolic pressure (EDP) and end-diastolic wall stress (EDWS) in a dose-dependent manner.
CXL-1020 is a hydroxylamine-based nitroxyl (HNO) donor. CXL-1020 improves cardiac inotropy/lusitropy and Ca2+ cycling in rats with abnormal relaxation. CXL-1020 induces vasorelaxation and improves cardiac function in canine models. CXL-1020 has been used to research systolic heart failure and stable heart failure.
体内研究：
CXL-1020 (100 μg/kg/min; infusion for 30 min) improves hemodynamics and cardiac function, and enhances both diastolic and systolic performance in mice.CXL-1020 (3 and 10 mg/kg/min; 4-hour intravenous infusion) improves left ventricular systolic and diastolic function in dogs with advanced heart failure.Animal Model:Adult male Sprague-Dawley rats (250-350 g; induced cardiac dysfunction byisoproterenol)
Dosage:100 μg/kg/min
Administration:For 30 min
Result:Improved hemodynamics and cardiac function in normal rats, and enhanced both diastolic and systolic performance in cardiac dysfunction mice.
Animal Model:Dogs (coronary microembolization-induced heart failure)3 and 10 mg/kg/min
Dosage:3 and 10 mg/kg/min
Administration:4-hour intravenous infusion
Result:Decreased systolic aortic pressure (AoP) modestly; significantly increased EF and deceleration time of early mitral inflow velocity (DT) and significantly lowered left ventricular (LV) end-systolic volume (ESV), LV end-diastolic pressure (EDP) and end-diastolic wall stress (EDWS) in a dose-dependent manner.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备